BOSTON--(BUSINESS WIRE)--Human Metabolome Technologies, Inc. (HMT), the leading developer of capillary electrophoresis mass spectrometry (CE-MS) based metabolomics, has been recognized by the National Cancer Center’s Office of Science and Technology Resources (OSTR) as a preferred vendor of metabolomic services. Under this program, new technology costs are subsidized by the OSTR in an effort to advance cancer research for NCI's Center for Cancer Research (CCR) investigators.
Alexander Buko, Ph.D., Vice President of HMT said, “We are excited by this new partnership. The NCI has acknowledged that we have a unique technology that researchers can benefit from.” HMT is making available their landmark CARCINOSCOPE™ analysis package. “CARCINOSCOPE is the only quantitative metabolite profiling option available to researchers and having the NCI recognize the impact of this technology is a testament to the quality of data we provide,” said Dr. Buko. “Whether you are directly targeting metabolic pathways or commonly mutated signaling pathways, the cancer cells’ metabolism will be altered. Integrating metabolic studies with traditional genetic and proteomic studies is the only way to get a full picture of cancer. CARCINOSCOPE™ was specifically designed for those affected metabolic pathways.”
Human Metabolome Technologies, Inc., (HMT) was founded in 2003 by Professor Masaru Tomita, Ph.D., Director of the Institute for Advanced Biosciences (IAB), Keio University, Japan, and by IAB’s Professor Tomoyoshi Soga, Ph.D. A Japan-based biotechnology company, HMT provides capillary electrophoresis mass spectrometry based metabolomics services, aiming to provide complete solutions for metabolomics research in biomarker discovery, drug design, diagnostic technology and food production.